Novo Nordisk AS
NVO
Company Profile
Business description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
E: phak@novonordisk.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
76,302
Novo Nordisk AS News & Analysis
stocks
Obesity drug stocks: Why it will be ‘exceptionally difficult’ to dethrone Eli Lilly and Novo Nordisk
The two biggest players in the market appear poised to dominate for years to come.
stocks
Obesity drug stocks: Where to invest now
Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,398.60 | 80.20 | -0.95% |
| CAC 40 | 8,199.71 | 88.08 | 1.09% |
| DAX 40 | 23,147.02 | 595.59 | 2.64% |
| Dow JONES (US) | 43,191.24 | 649.67 | -1.48% |
| FTSE 100 | 8,871.31 | 61.57 | 0.70% |
| HKSE | 22,744.14 | 262.13 | -1.14% |
| NASDAQ | 18,350.19 | 497.09 | -2.64% |
| Nikkei 225 | 37,096.51 | 688.96 | -1.82% |
| NZX 50 Index | 12,419.20 | 130.85 | -1.04% |
| S&P 500 | 5,849.72 | 104.78 | -1.76% |
| S&P/ASX 200 | 8,175.50 | 70.20 | -0.85% |
| SSE Composite Index | 3,313.70 | 3.22 | -0.10% |